About

Non-Invasive Precision Oncology

Novel Approach for Stage IV Cancer Care

At New Phase, we are dedicated to transforming the approach to advanced cancer care, particularly in patients with stage IV cancer.

Our mission is to dramatically improve cancer patients' quality of life through innovative and minimally invasive treatments. By leveraging nanotechnology and electromagnetic systems, we provide a precise, groundbreaking solution to one of the world’s biggest health challenges - Cancer.

New Phase’s Approach

New Phase has pioneered the development of a unique treatment system comprising two innovative components: the Sarah Nanoparticle (SaNP) and an Electromagnetic Induction System (EIS). These components work in tandem to deliver a targeted, non-invasive treatment that destroys cancerous cells while preserving healthy tissue. Our technology is designed to transform cancer from a terminal illness into a manageable condition, improving both patient outcomes and quality of life.

Sarah Nanoparticles (SaNP)

Biocompatible nanoparticles designed to target and destroy malignant cells by inducing hyperthermic cell death without harming surrounding healthy tissue.

Electromagnetic Induction System (EIS)

A system that applies a non-ionizing electromagnetic field that heats SaNPs to a controlled temperature of 50°C, ensuring that cancer cells are effectively destroyed while minimizing damage to normal tissues.

Ongoing Research and Development

We are dedicated to the continuous advancement of our technology through rigorous research and clinical trials. Currently, New Phase is conducting an early feasibility clinical trial in Israel, with results expected by Q1 2025 and plan to initiate an early feasibility trial in the U.S. by Q1 2025.
Preliminary results indicate stabilization of the disease in some cases, with no toxic nor any severe side effects, making it safe to use.

The Sarah Nanotechnology System is classified as a Class III medical device, recognized by regulatory authorities such as the FDA and the Israeli Ministry of Health for its advanced, life-saving potential. New Phase holds 13 granted patents across the U.S., EU, Japan, Israel, Canada, China, and India, further solidifying our position as a leader in cancer treatment innovation.

Our Vision and Values

Our vision is clear: to develop innovative treatments that offer new hope and significantly improve the outcomes for patients with advanced cancer. New Phase’s work is shaped by core values that reflect our commitment to patient care and scientific progress, while generating sustainable value for shareholders:

Innovation

Continuously driving the boundaries of electromagnetic hyperthermia in order to offer better cancer treatment with innovative solutions

Collaboration

Working hand-in-hand with leading oncology hospitals to develop practical, effective treatment

Perseverance

Driven to overcome challenges and improve cancer care, relentlessly striving for better patient outcomes and business performances.

Our journey is fueled by the promise of delivering innovative solutions that redefine the future of cancer care

At New Phase, we are driven by a relentless pursuit of scientific excellence and challenging traditional oncology paradigms. By pushing the boundaries of technology to improve cancer treatments, we aim to develop transformative therapies that not only prolong lives but also improve the overall quality of life for patients.

Our Team

Groundbreaking technology is developed by a visionary leadership and dedicated team of experts. Our multidisciplinary team includes Ph.D. and M.Sc. holders in chemistry, physics, biology, and engineering, all working together to advance cancer treatment.

Ofer  Shalev

Chief Executive Officer, Co-Founder and Member of the Board

Over 25 years of management experience predominantly in the Hi-tech and Bio-tech industry and V.P Operation in the banking sector.

MBA – University of Edinburgh

Ofer  Shalev

Chief Executive Officer, Co-Founder and Member of the Board

Over 25 years of management experience predominantly in the Hi-tech and Bio-tech industry and V.P Operation in the banking sector.

MBA – University of Edinburgh

Uri Ben-Or

CFO

Over 25 years of broad experience in corporate finance, accounting, M&A transactions, and IPOs. He has significant expertise, including serving as CFO, with public life science companies traded on the TASE, OTC, and Nasdaq. He provides his services to New Phase through CFO Direct, a company which he founded and serves as CEO.Prior to founding CFO Direct he served as the VP Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks, where he led all the corporate finance activities, fund raising and legal aspects of the company. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PriceWaterhouseCoopers. Uri holds a BA degree in Business from the College of Administration, an MBA from Bar-Ilan University, and is a Certified Public Accountant.

Uri Ben-Or

CFO

Over 25 years of broad experience in corporate finance, accounting, M&A transactions, and IPOs. He has significant expertise, including serving as CFO, with public life science companies traded on the TASE, OTC, and Nasdaq. He provides his services to New Phase through CFO Direct, a company which he founded and serves as CEO.Prior to founding CFO Direct he served as the VP Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks, where he led all the corporate finance activities, fund raising and legal aspects of the company. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PriceWaterhouseCoopers. Uri holds a BA degree in Business from the College of Administration, an MBA from Bar-Ilan University, and is a Certified Public Accountant.

Irie Meltzer

VP Business Development

An experienced business executive, with over 12 years’ experience in global Business Development, Sales, and Marketing, specializing in medical devices, high-tech, and financial sectors.
Vast experience and management skills of people, projects, and building markets and teams.
Irie holds a Global MBA in International Business Administration from The IDC in Herzliya, majored in Innovation, Entrepreneurship, and Finance.

Irie Meltzer

VP Business Development

An experienced business executive, with over 12 years’ experience in global Business Development, Sales, and Marketing, specializing in medical devices, high-tech, and financial sectors.
Vast experience and management skills of people, projects, and building markets and teams.
Irie holds a Global MBA in International Business Administration from The IDC in Herzliya, majored in Innovation, Entrepreneurship, and Finance.

Meirav Hirsh Kovacs

VP RA & Clinical

Over 20 years of experience in the medical device arena, mainly in clinical and Regulatory Affairs. Extensive experience leading clinical studies and global regulatory submissions. Previous Clinical & Regulatory Managerial positions at Medtronic, SuperDimension and IceCure Medical.
Meirav graduated M.Sc. with honors in Biochemistry, from Tel-Aviv University.

Meirav Hirsh Kovacs

VP RA & Clinical

Over 20 years of experience in the medical device arena, mainly in clinical and Regulatory Affairs. Extensive experience leading clinical studies and global regulatory submissions. Previous Clinical & Regulatory Managerial positions at Medtronic, SuperDimension and IceCure Medical.
Meirav graduated M.Sc. with honors in Biochemistry, from Tel-Aviv University.

Doron Suchi

VP R&D and Site Manager

Over 15 years of managing R&D and engineering groups, with vast local and global experience.
Suchi holds a B.Sc. in Electrical Engineering and M.Sc. in Industrial Management engineering, both from Ben Gurion University.
He has proven experience in the medical world, both from leading R&D teams in a large corporate, Medtronic and in startup companies.

Doron Suchi

VP R&D and Site Manager

Over 15 years of managing R&D and engineering groups, with vast local and global experience.
Suchi holds a B.Sc. in Electrical Engineering and M.Sc. in Industrial Management engineering, both from Ben Gurion University.
He has proven experience in the medical world, both from leading R&D teams in a large corporate, Medtronic and in startup companies.

Galit Hirsch

VP of HR

Extensive international experience, including senior HR roles in global Pharmaceutical and Medical Device companies. Served as VP HR at Tuttnauer and at A.L. Group. Galit holds an M.Sc. in Organizational Behavior and a BA in Behavioral Science from Ben Gurion University, specializing in Business Management and Human Resources.

Galit Hirsch

VP of HR

Extensive international experience, including senior HR roles in global Pharmaceutical and Medical Device companies. Served as VP HR at Tuttnauer and at A.L. Group. Galit holds an M.Sc. in Organizational Behavior and a BA in Behavioral Science from Ben Gurion University, specializing in Business Management and Human Resources.

Dr. Sarah Kraus (PhD)

Director of Biology & Principal Scientist

Previously Head of the laboratory of Molecular Biology at the Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, and Research Associate at the University of Virginia. PhD in Cell biology and Immunology from Tel Aviv University, Post Doc at the Weizmann Institute of Science, MBA in Biomedical Management, and M.Med.Sc. in Clinical Biochemistry.

Dr. Sarah Kraus (PhD)

Director of Biology & Principal Scientist

Previously Head of the laboratory of Molecular Biology at the Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, and Research Associate at the University of Virginia. PhD in Cell biology and Immunology from Tel Aviv University, Post Doc at the Weizmann Institute of Science, MBA in Biomedical Management, and M.Med.Sc. in Clinical Biochemistry.

Boaz Shalev

Head of Engineering

Over 10 years in the medical device industry as an R&D physicist.
Experienced in development of multidisciplinary systems from prototype to final product such as new PET-CT scanner at GE Healthcare, Capnography monitor at Medtronic, and non-invasive blood glucose monitoring.
Boaz holds a B.Sc. in Physics from the Technion institute of technology.

Boaz Shalev

Head of Engineering

Over 10 years in the medical device industry as an R&D physicist.
Experienced in development of multidisciplinary systems from prototype to final product such as new PET-CT scanner at GE Healthcare, Capnography monitor at Medtronic, and non-invasive blood glucose monitoring.
Boaz holds a B.Sc. in Physics from the Technion institute of technology.

Dr. Pazit Rukenstein (PhD)

Head of Chemistry Production

Chemist and Materials Scientist with 8 years of experience in the Nanotechnology field. Vast experience in nanoparticles synthesis and hybrid nanoparticles for catalytic process. Ph.D and M.Sc in Nanotechnology field from Ben-Gurion university.

Dr. Pazit Rukenstein (PhD)

Head of Chemistry Production

Chemist and Materials Scientist with 8 years of experience in the Nanotechnology field. Vast experience in nanoparticles synthesis and hybrid nanoparticles for catalytic process. Ph.D and M.Sc in Nanotechnology field from Ben-Gurion university.

Dr. Rinat Meir (PhD)

Head of Chemistry Research & Development

Rinat is a multidisciplinary scientist with over 10 years of experience and expertise in nanoparticles and formulation development. Rinat holds a PhD in Nanotechnology and an MSc in Chemistry from the Hebrew University of Jerusalem. Rinat has experience as a research fellow at Columbia University in New York and has managed and led Biotech R&D projects at the interface of chemistry and medicine.

Dr. Rinat Meir (PhD)

Head of Chemistry Research & Development

Rinat is a multidisciplinary scientist with over 10 years of experience and expertise in nanoparticles and formulation development. Rinat holds a PhD in Nanotechnology and an MSc in Chemistry from the Hebrew University of Jerusalem. Rinat has experience as a research fellow at Columbia University in New York and has managed and led Biotech R&D projects at the interface of chemistry and medicine.

Udi Ron

Quality Assurance Director

Over 15 years of experience in the Medical device industry in Quality Assurance, Regulatory Affairs, preclinical and clinical research, and physicians training of multidisciplinary medical devices.
In-depth technical understanding of medical devices. Extensive experience in compliance with FDA regulations, ISO 13485 Quality System standard, Good Laboratory Practices (GLP), Good Clinical Practice (GCP)
M.Sc in Medical Science from Tel Aviv University.

Udi Ron

Quality Assurance Director

Over 15 years of experience in the Medical device industry in Quality Assurance, Regulatory Affairs, preclinical and clinical research, and physicians training of multidisciplinary medical devices.
In-depth technical understanding of medical devices. Extensive experience in compliance with FDA regulations, ISO 13485 Quality System standard, Good Laboratory Practices (GLP), Good Clinical Practice (GCP)
M.Sc in Medical Science from Tel Aviv University.

Dr. Arnoldo Cyjon, M.D.

Oncologist

Recognized KOL in the field of lung and liver cancer. Dr. Cyjon’s role within the Company includes scientific advisory, and he is the Company’s CMO. Dr. Cyjon was formerly the Deputy Head of the Oncology Department at Assaf Harofeh Hospital (Shamir Medical Centre) in Israel, where he was responsible for clinical trials in invasive oncology, regional treatment, and lung cancer treatment. Dr. Arnoldo Cyjon is retained as an employee and holds shares under our ESOP.

Dr. Arnoldo Cyjon, M.D.

Oncologist

Recognized KOL in the field of lung and liver cancer. Dr. Cyjon’s role within the Company includes scientific advisory, and he is the Company’s CMO. Dr. Cyjon was formerly the Deputy Head of the Oncology Department at Assaf Harofeh Hospital (Shamir Medical Centre) in Israel, where he was responsible for clinical trials in invasive oncology, regional treatment, and lung cancer treatment. Dr. Arnoldo Cyjon is retained as an employee and holds shares under our ESOP.

Prof. Glenwood Goss, M.D

Oncologist

Recognized KOL in the field of thoracic cancer. Prof. Goss provides the Company consultancy in regulatory aspects along with communication activities with hospitals. Prof. Goss is Chair of the Thoracic Oncology Site Committee NCIC CTG, Professor of Medicine at the University of Ottawa, and Director of Clinical and Translational Research at the Ottawa Hospital Cancer Centre. For the past eight years, Prof. Goss has served on the IND Executive, NCIC CTG. He is on the editorial board of several peer-reviewed journals, including the Journal of Clinical Oncology and the Journal of Clinical Lung Cancer, and he chairs the Publications Committee of the International Association for the Study of Lung Cancer. Prof. Goss’s areas of interest are early cancer drug development and thoracic oncology. Prof. Goss holds shares under our ESOP.

Prof. Glenwood Goss, M.D

Oncologist

Recognized KOL in the field of thoracic cancer. Prof. Goss provides the Company consultancy in regulatory aspects along with communication activities with hospitals. Prof. Goss is Chair of the Thoracic Oncology Site Committee NCIC CTG, Professor of Medicine at the University of Ottawa, and Director of Clinical and Translational Research at the Ottawa Hospital Cancer Centre. For the past eight years, Prof. Goss has served on the IND Executive, NCIC CTG. He is on the editorial board of several peer-reviewed journals, including the Journal of Clinical Oncology and the Journal of Clinical Lung Cancer, and he chairs the Publications Committee of the International Association for the Study of Lung Cancer. Prof. Goss’s areas of interest are early cancer drug development and thoracic oncology. Prof. Goss holds shares under our ESOP.

Prof. Zeev Rotstein, MD, MHA

Cardiologist and health management executive

Cardiologist and health management executive (M.H.A.) with extensive medical operations management experience within complex healthcare systems. Prof. Zeev Rotstein’s role within the Company includes scientific advisory. Prof. Zeev Rotstein has a wide range of international experience in hospital planning, development, and construction at both the Hadassah Medical Center (2016-2021) and the Sheba Medical Centre (2004-2016). He is an Associate Clinical Professor who has published more than 100 articles in peer-reviewed journals. His membership in numerous professional societies and organizations includes the Israel Medical Association, Israel Heart Society, European Heart Society, and the Israel Association of Hospital Managers. Prof. Zeev Rotstein holds shares under our ESOP.

Prof. Zeev Rotstein, MD, MHA

Cardiologist and health management executive

Cardiologist and health management executive (M.H.A.) with extensive medical operations management experience within complex healthcare systems. Prof. Zeev Rotstein’s role within the Company includes scientific advisory. Prof. Zeev Rotstein has a wide range of international experience in hospital planning, development, and construction at both the Hadassah Medical Center (2016-2021) and the Sheba Medical Centre (2004-2016). He is an Associate Clinical Professor who has published more than 100 articles in peer-reviewed journals. His membership in numerous professional societies and organizations includes the Israel Medical Association, Israel Heart Society, European Heart Society, and the Israel Association of Hospital Managers. Prof. Zeev Rotstein holds shares under our ESOP.

Prof. Dan Peer

VP for Research and Development at Tel Aviv University

Director of the Laboratory of Precision Nano Medicine at Tel Aviv University (TAU), a national nanomedicine initiative project. Prof. Dan Peer’s role within the Company includes scientific advisory. Prof. Dan Peer is a Director of the Leona M. and Harry B. Helmsley Nanotechnology Research Fund and member of the Tel Aviv University Cancer Biology Research Centre, the largest Israeli cancer center that includes 17 affiliated hospitals. Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system, and he pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system, with enormous implications for cancer and inflammation. Prof. Dan Peer holds shares under our ESOP.

Prof. Dan Peer

VP for Research and Development at Tel Aviv University

Director of the Laboratory of Precision Nano Medicine at Tel Aviv University (TAU), a national nanomedicine initiative project. Prof. Dan Peer’s role within the Company includes scientific advisory. Prof. Dan Peer is a Director of the Leona M. and Harry B. Helmsley Nanotechnology Research Fund and member of the Tel Aviv University Cancer Biology Research Centre, the largest Israeli cancer center that includes 17 affiliated hospitals. Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system, and he pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system, with enormous implications for cancer and inflammation. Prof. Dan Peer holds shares under our ESOP.

Ofer  Shalev

Chief Executive Officer, Co-Founder and Member of the Board

Over 25 years of management experience predominantly in the Hi-tech and Bio-tech industry and V.P Operation in the banking sector.

MBA – University of Edinburgh

Ofer  Shalev

Chief Executive Officer, Co-Founder and Member of the Board

Over 25 years of management experience predominantly in the Hi-tech and Bio-tech industry and V.P Operation in the banking sector.

MBA – University of Edinburgh

Dr. Rafael Hof (PhD)

Co-Founder and Member of the Board

Rafi has a remarkable ability to combine several technologies into one solution. He holds a PhD in Mechanical Engineering, a BSc in Physics, a BSc in Chemistry, and a BSc in Biology, and he owns more than 15 patents. Rafi has held senior positions in several medical hi-tech companies such as Redent Nova, Versamed, Lumenis, Bypass.

Dr. Rafael Hof (PhD)

Co-Founder and Member of the Board

Rafi has a remarkable ability to combine several technologies into one solution. He holds a PhD in Mechanical Engineering, a BSc in Physics, a BSc in Chemistry, and a BSc in Biology, and he owns more than 15 patents. Rafi has held senior positions in several medical hi-tech companies such as Redent Nova, Versamed, Lumenis, Bypass.

Prof. Zeev Rotstein, MD, MHA

Cardiologist and health management executive

Cardiologist and health management executive (M.H.A.) with extensive medical operations management experience within complex healthcare systems. Prof. Zeev Rotstein’s role within the Company includes scientific advisory. Prof. Zeev Rotstein has a wide range of international experience in hospital planning, development, and construction at both the Hadassah Medical Center (2016-2021) and the Sheba Medical Centre (2004-2016). He is an Associate Clinical Professor who has published more than 100 articles in peer-reviewed journals. His membership in numerous professional societies and organizations includes the Israel Medical Association, Israel Heart Society, European Heart Society, and the Israel Association of Hospital Managers. Prof. Zeev Rotstein holds shares under our ESOP.

Prof. Zeev Rotstein, MD, MHA

Cardiologist and health management executive

Cardiologist and health management executive (M.H.A.) with extensive medical operations management experience within complex healthcare systems. Prof. Zeev Rotstein’s role within the Company includes scientific advisory. Prof. Zeev Rotstein has a wide range of international experience in hospital planning, development, and construction at both the Hadassah Medical Center (2016-2021) and the Sheba Medical Centre (2004-2016). He is an Associate Clinical Professor who has published more than 100 articles in peer-reviewed journals. His membership in numerous professional societies and organizations includes the Israel Medical Association, Israel Heart Society, European Heart Society, and the Israel Association of Hospital Managers. Prof. Zeev Rotstein holds shares under our ESOP.

Edgar Depichoto

Edgar de Picciotto is a Partner at Tendência Wealth Management in São Paulo, Brazil.
Has more than 20 years of experience in financial markets including relevant roles in corporate and project financing; structured finance and private banking in institutions such as BNP Paribas, KPMG, Bank Hapoalim and RBC. For the last 10 years has focused on the origination, structuring and distribution of both, debt and equity type deals, mainly in the fixed income, real estate and venture capital asset classes. Has specialized to work with and for high networth private individuals in Brazil and internationally.
On the venture capital side of the business, Edgar has assisted companies in Brazil and Israel to raise funds in pre-seed, seed and series A rounds. Has an active role in the reporting of results, ongoing activities and corporate governance to investors. In many of the invested companies, he has a significant participation in the development of funding structures and solutions.
Edgar has a Public Administration Degree in Fundação Getúlio Vargas – FGV – SP as well as an Executive Finance MBA in Instituto Brasileiro de Mercado de Capitais – IBMEC – SP. He is fluent in English, French and Portuguese. Born in São Paulo, Brazil, on the 2nd of December of 1977, is married to Sandra, and father of Joe (17), Rachel (15) and Jim (11).

Edgar Depichoto

Edgar de Picciotto is a Partner at Tendência Wealth Management in São Paulo, Brazil.
Has more than 20 years of experience in financial markets including relevant roles in corporate and project financing; structured finance and private banking in institutions such as BNP Paribas, KPMG, Bank Hapoalim and RBC. For the last 10 years has focused on the origination, structuring and distribution of both, debt and equity type deals, mainly in the fixed income, real estate and venture capital asset classes. Has specialized to work with and for high networth private individuals in Brazil and internationally.
On the venture capital side of the business, Edgar has assisted companies in Brazil and Israel to raise funds in pre-seed, seed and series A rounds. Has an active role in the reporting of results, ongoing activities and corporate governance to investors. In many of the invested companies, he has a significant participation in the development of funding structures and solutions.
Edgar has a Public Administration Degree in Fundação Getúlio Vargas – FGV – SP as well as an Executive Finance MBA in Instituto Brasileiro de Mercado de Capitais – IBMEC – SP. He is fluent in English, French and Portuguese. Born in São Paulo, Brazil, on the 2nd of December of 1977, is married to Sandra, and father of Joe (17), Rachel (15) and Jim (11).

Arik Luchatch

Represent the group of shareholders that founded New Phase. Arik is a serial investor. Fox Star, Polypid and many others.

Arik Luchatch

Represent the group of shareholders that founded New Phase. Arik is a serial investor. Fox Star, Polypid and many others.

Ready to learn more about how we're changing cancer treatment?